SAN FRANCISCO, May 3, 2021 /PRNewswire/ -- Kindred
Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company
focused on saving and improving the lives of pets, will release its
first quarter 2021 financial results on May
11, 2021, after the market close. The Company will host a
conference call at 4:30 p.m. Eastern
time/1:30 p.m. Pacific time
that day.
Access the call by dialing toll-free (855) 433-0927 from the
U.S. or (484) 756-4262 internationally, and using conference
ID 7573679.
The call will also be webcast live here, with a replay available
at that link for 30 days.
About Kindred Biosciences
Kindred Biosciences is a biopharmaceutical company developing
innovative biologics focused on saving and improving the lives of
pets. Its mission is to bring to pets the same kinds of safe and
effective medicines that human family members enjoy. The company's
strategy is to identify targets that have already demonstrated
safety and efficacy in humans and to develop therapeutics based on
these validated targets for dogs and cats. KindredBio has a deep
pipeline of novel biologics in development across many therapeutic
classes, alongside state-of-the-art biologics manufacturing
capabilities and a broad intellectual property portfolio.
For more information, visit: www.kindredbio.com
Contact
Katja Buhrer
katja.buhrer@kindredbio.com
(917) 969-3438
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kindred-biosciences-to-announce-first-quarter-2021-financial-results-301281866.html
SOURCE Kindred Biosciences, Inc.